Relay Therapeutics, Inc. Common Stock

RLAYNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
19.75 USD
↗ 0.06 (0.31%)AT CLOSE (11:59 AM EDT)
19.59
↘ 0.16 (0.84%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
19.59
↘ 0.16 (0.84%)
🔴Market: CLOSED

Relay Therapeutics, Inc. Common Stock (RLAY) trades at $19.71 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, RLAY is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Aug 6, 2026.

Open?$19.71
High?$20.26
Low?$19.50
Prev. Close?$19.69
Volume?2.4M
Avg. Volume?3.3M
VWAP?$19.70
Rel. Volume?0.73x
Bid / Ask
Bid?$19.00 × 100
Ask?$20.40 × 100
Spread?$1.40
Midpoint?$19.70
Valuation & Ratios
Market Cap?4.3B
Shares Out?191.6M
Float?116.7M
Float %?65.3%
P/E Ratio?N/A
P/B Ratio?6.68
EPS?-$1.25
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
192
Market Cap
4.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.relaytx.com
Listed
2020-07-16
Address
60 HAMPSHIRE STREET
CAMBRIDGE, MA 02139
Phone: 617-370-8837
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
100
Momentum?
25
Short Sent.?
30
Piotroski F-Score?1/9Weak
Altman Z-Score?40.35Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?36.47%Squeeze Risk
Short Interest?42.6M
Days to Cover?13.4
Free Float116.7M
Avg Daily Volume3.2M
Settlement Date2026-07-15
Financial Health
Current Ratio?22.13Strong
Quick Ratio?22.13Strong
Cash Ratio?6.88Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
28
6.68FAIR▾
P/S?
Peers
100
S&P
3
401.91HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-13.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
382.75HIGH▾
Returns & Efficiency
ROE?
S&P
3
-42.5%WEAK▾
ROA?
S&P
3
-39.0%WEAK▾
Cash Flow & Enterprise
FCF?$-213383000
Enterprise Value?$4.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist